Fujino Yoshihiko, Takahashi Chisato, Mitsumoto Kensuke, Uzu Takashi
Nephrology, Nippon Life Hospital, Osaka, Japan.
Nephrology and Blood Purification, Nippon Life Hospital, Osaka, Japan.
BMJ Case Rep. 2019 Jan 29;12(1):e227756. doi: 10.1136/bcr-2018-227756.
Anticoagulants have recently been recognised as a cause of acute kidney injury (AKI). We describe the case of a 75-year-old man with IgA vasculitis and atrial fibrillation treated with rivaroxaban, who presented with macroscopic haematuria and an acute decline in renal function. Two months before referral, he noted palpable purpuric lesions and was diagnosed with IgA vasculitis based on skin biopsy findings; the skin lesion disappeared following treatment with a steroid external preparation. Renal biopsy revealed glomerular haemorrhage and red blood cell casts. Although rivaroxaban was withdrawn, his kidney function worsened and he was started on haemodialysis. His renal function did not recover. To the best of our knowledge, this is the first case of direct oral anticoagulant (DOAC)-related AKI in systemic vasculitis. During DOAC therapy, close monitoring of a patient's urinalysis results and their renal function may be required for patients with systemic vasculitis to avoid AKI.
抗凝剂最近被认为是急性肾损伤(AKI)的一个病因。我们描述了一例75岁男性患者,患有IgA血管炎和心房颤动,接受利伐沙班治疗,出现肉眼血尿和肾功能急性下降。在转诊前两个月,他注意到可触及的紫癜性病变,根据皮肤活检结果被诊断为IgA血管炎;使用类固醇外用制剂治疗后皮肤病变消失。肾活检显示肾小球出血和红细胞管型。尽管停用了利伐沙班,但他的肾功能仍恶化,开始进行血液透析。他的肾功能没有恢复。据我们所知,这是系统性血管炎中首例与直接口服抗凝剂(DOAC)相关的AKI病例。在DOAC治疗期间,对于系统性血管炎患者,可能需要密切监测其尿液分析结果和肾功能,以避免发生AKI。